Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
714 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, et al. · N Engl J Med · 2024Randomized Controlled Trial, Multicenter Study
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · N Engl J Med · 2023Equivalence Trial, Multicenter Study
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
Galli M, Benenati S, Laudani C, et al. · J Am Coll Cardiol · 2025Systematic Review, Meta-Analysis
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L, Wang J, Ping F, et al. · JAMA Intern Med · 2022Meta-Analysis, Systematic Review
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
Bonaca MP, Catarig AM, Houlind K, et al. · Lancet · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Packer M, Zile MR, Kramer CM, et al. · N Engl J Med · 2025Clinical Trial, Phase III, Multicenter Study
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, et al. · Ann Intern Med · 2020Comparative Study, Research Support, Non-U.S. Gov't
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, et al. · N Engl J Med · 2021Comparative Study, Multicenter Study
- Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
Badve SV, Bilal A, Lee MMY, et al. · Lancet Diabetes Endocrinol · 2025Meta-Analysis, Systematic Review
- Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
Sandsdal RM, Juhl CR, Jensen SBK, et al. · Cardiovasc Diabetol · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA, Patel RA, Merrill P, et al. · Lancet Diabetes Endocrinol · 2018Meta-Analysis, Research Support, Non-U.S. Gov't
- Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Marx N, Deanfield JE, Mann JFE, et al. · Circulation · 2025Clinical Trial, Phase III, Multicenter Study
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC, Tendal B, Mustafa RA, et al. · BMJ · 2021Systematic Review, Network Meta-Analysis
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
McGuire DK, Marx N, Mulvagh SL, et al. · N Engl J Med · 2025Multicenter Study, Randomized Controlled Trial
- Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.
Seminer A, Mulihano A, O'Brien C, et al. · JAMA Neurol · 2025Meta-Analysis, Systematic Review
- Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Lee MMY, Sattar N, Pop-Busui R, et al. · Diabetes Care · 2025Systematic Review, Meta-Analysis
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Jastreboff AM, Kaplan LM, Davies MJ, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, et al. · Lancet · 2018Multicenter Study, Randomized Controlled Trial
- Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Kosiborod MN, Deanfield J, Pratley R, et al. · Lancet · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Neuen BL, Fletcher RA, Heath L, et al. · Circulation · 2024Systematic Review, Meta-Analysis
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Deanfield J, Lincoff AM, Kahn SE, et al. · Lancet · 2025Randomized Controlled Trial, Multicenter Study
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Sattar N, McGuire DK, Pavo I, et al. · Nat Med · 2022Meta-Analysis, Research Support, Non-U.S. Gov't
- Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M, Nreu B, Scatena A, et al. · Diabetes Obes Metab · 2017Meta-Analysis, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.